Enara Bio

Description: Enara Bio develops next-gen cancer immunotherapies by targeting unconventional MR1 ligands & Dark Antigens™ to treat broad patient populations.

Country: UK

Based in: London

Founded: 2016

Funding Stage: Series A/B

Tags: ['Biotechnology', 'Therapeutics']

Categories

Add insights to your inbox

We’ll send you content you’ll want to read- and put to use.

Details about how we process your information are available in our Privacy Policy.